Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2018

View Archived Issues

ANI Pharmaceuticals acquires NDAs, U.S. rights to four AstraZeneca products

CStone Pharmaceuticals announces IND filing in Australia

FDA clears Ignyta's IND for RXDX-106 study

Wanbang Biopharmaceuticals submits IND in China for SGLT2 inhibitor

FDA accepts Progenics' Azedra NDA for review

Siglec-7 targeting shows promise against multiple myeloma

Galapagos and Servier report ADAMTS inhibitors for osteoarthritis

CXCL12 shown to impact tipifarnib benefit in AML and MDS patients

Oncimmune signs framework agreement with Genostics for EarlyCDT platform in China

Vitae Pharmaceuticals patents Menin/MLL interaction inhibitors

GABA(A) receptor agonists reported in Sichuan Haisco Pharmaceutical patent

Phase III study of EG-1962 in aneurysmal subarachnoid hemorrhage recommended to continue

Universita del Piemonte Orientale prepares and tests CRAC modulators

GlaxoSmithKline patents describe ATF4 inhibitors

Atara cleared to begin phase III studies of tabelecleucel

Servier and Vernalis jointly patent USP7 inhibitors

ImmunoPrecise Antibodies invests in SERPINx to develop serine protease inhibitors

SELLAS Life Sciences Group completes merger with Galena Biopharma

Bio-Path updates pipeline progress

Global Foundation for Human Aging Research funds research at Dana-Farber into cellular aging

PHF2 expression impacts survival of ALL patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...